Skip to main content
SpringerLink
Log in

Drug development risk and the cost of capital

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Cost of capital variations.

References

  1. Stewart, J. J. & Bonifant, B. The valuation high ground. Nature Biotech. 27, 1–3 (2009).

    Article  Google Scholar 

  2. Myers, S. C. & Shyam Sundar, L. in Competitive Strategies in the Pharmaceutical Industry (ed. Helms, R. B.) 10, 208–237 (AEI Press, Washington DC, 1996).

    Google Scholar 

  3. Myers, S. C. & Howe, C. D. A life-cycle financial model of pharmaceutical R&D. MIT Program on the Pharmaceutical Industry (MIT Sloan School of Management, 1997).

    Google Scholar 

  4. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge D. T. Robinson and E. B. Rasiel for guidance on the methodologies for deriving COC estimates. We thank S. C. Myers for helpful discussions on time-varying discount rates and their use in drug development. We also thank K. Chenet for providing data on development phase for some companies in the data set.

Author information

Authors and Affiliations

  1. Aris I. Baras and Kevin A. Schulman are at the Duke University School of Medicine, Durham, North Carolina, 27710, USA, and at the Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina 27708, USA.,

    Aris I. Baras & Kevin A. Schulman

  2. Aris I. Baras is also at Liquidia Technologies, Morrisville, North Carolina 27560, USA.,

    Aris I. Baras

  3. Alex S. Baras is at the Johns Hopkins Hospital, Baltimore, Maryland, 21287, USA.,

    Alex S. Baras

Authors
  1. Aris I. Baras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex S. Baras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin A. Schulman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin A. Schulman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information Box S1

Analysis methodology and data (PDF 212 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baras, A., Baras, A. & Schulman, K. Drug development risk and the cost of capital. Nat Rev Drug Discov 11, 347–348 (2012). https://doi.org/10.1038/nrd3722

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3722

  • Springer Nature Limited

This article is cited by

Search

Navigation